Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Metformin – Forschungsarchiv – Seite 19 von 24 | SupStack

Metformin – Forschungsarchiv

Studien 1851–1900 von 2110, neueste zuerst

Die 1000 neuesten Studien – mit Evidenz-Zusammenfassung, Filtern und Suche – stehen auf der Hauptseite. Dieses Archiv listet die übrigen, 50 pro Seite. Zurück zur Hauptseite

1851RCT2005

Roden M, Laakso M, Johns D, Widel M, Urquhart R, Richardson C · Diabet Med (2005)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

Metformin – Forschungsarchiv

Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus.

Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.

Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome.

Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome.

The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus.

High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception.

Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus.

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.

Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies.

Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment.

Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients.

Dietary intake in the diabetes prevention program cohort: baseline and 1-year post randomization.

Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.

Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes.

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.

Metformin in the treatment of patients with non-alcoholic steatohepatitis.

Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.

Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.

Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study.

A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study.

Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial.

Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women.

Impact of metformin on glucose metabolism in nondiabetic, obese African Americans: a placebo-controlled, 24-month randomized study.

Durable efficacy of metformin/glibenclamide combination tablets (Glucovance) during 52 weeks of open-label treatment in type 2 diabetic patients with hyperglycaemia despite previous sulphonylurea monotherapy.

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.

Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome.

Metformin in polycystic ovary syndrome.

Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.

Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.

Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study.

Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.

Does metformin induce ovulation in normoandrogenic anovulatory women?

Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.

Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome.

The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results.

Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin.

Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome.

The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial.

Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients.

Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide.

The effect of metformin treatment to ovarian response in cases with PCOS.

Comparison of pioglitazone and metformin efficacy using homeostasis model assessment.

Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.

Effect of metformin vs. placebo treatment on serum fatty acids in non-diabetic obese insulin resistant individuals.

[Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study.